Treatment of conditions by toll-like receptor modulators

A method for treating a condition in a subject, comprising administering to the subject a compound having a structure according to Formula I:

• or a pharmaceutically acceptable salt thereof, including a hydrate thereof, wherein:
• X is N or CR2;
• R is —OR1, —SR1, or —NRaRb,
• X1 is a bond or is —O—, —S—, or —NRc—;
• Rc is hydrogen, C1-C10 alkyl, or substituted C1-C10 alkyl, or Rc and R1 taken together with the nitrogen atom can form a heterocyclic ring or a substituted heterocyclic ring;
• R′ is hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, C1-C10 alkoxy, substituted C1-C10 alkoxy, C1-C10 alkyl C1-C10 alkoxy, substituted C1-C10 alkyl C1-C10 alkoxy, C5-C10 aryl, substituted C5-C10 aryl, C5-C9 heterocyclic, substituted C5-C9 heterocyclic, C3-C9 carbocyclic or substituted C3-C9 carbocyclic;
• each R2 independently is —OH, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, —C(O)—C1-C6 alkyl (alkanoyl), substituted —C(O)—C1-C6 alkyl, —C(O)—C6-C10 aryl (aroyl), substituted —C(O)—C6-C10 aryl, —C(O)OH (carboxyl), —C(O)O—C1-C6 alkyl (alkoxycarbonyl), substituted —C(O)O—C1-C6 alkyl, —NRaRb, —C(O)NRaRb (carbamoyl), substituted C(O)NRaRb, halo, nitro, or cyano;
• the substituents on the alkyl, aryl or heterocyclic groups are hydroxy, C1-C6 alkyl, hydroxy C1-C6 alkylene, C1-C6 alkoxy, C3-C6 cycloalkyl, C1-C6 alkoxy C1-C6 alkylene, amino, cyano, halogen, or aryl;
• each Ra and Rb is independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl, C1-C6 alkanoyl, hydroxy C1-C6 alkyl, aryl, aryl C1-C6 alkyl, Het, Het C1-C6 alkyl, or C1-C6 alkoxycarbonyl;
• each X2 independently is a bond or a linking group;
• each R3 independently is a polyethylene glycol (PEG) moiety;
• each R4 independently is H, —C1-C6 alkyl, —C1-C6 alkoxy, —NRaRb, —OH, —CN, —COOH, —COOR1, —C1-C6 alkyl-NRaRb, —C1-C6 alkyl-OH, —C1-C6 alkyl-CN, —C1-C6 alkyl-COOH, —C1-C6 alkyl-COOR1, —R—CS—NR′R—, -optionally substituted 5-6 membered ring, or —C1-C6 alkyl-optionally substituted 5-6 membered ring;
• m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
• n is 0, 1, 2, 3 or 4;
• p is 1 to 100;
• q is 1, 2, 3, 4 or 5
• r is 1 to 1,000;
• s is 1 to 1,000;
• and
• the sum of n and q equals 5
• or a pharmaceutically acceptable salt, tautomer, or hydrate thereof, wherein the condition is kidney failure or kidney disease.